This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Nymox Pharmaceutical Corporation
Drug Names(s): NYM-4805, REC 0482, Fexapotide Triflutate
NX-1207 is a proprietary and undisclosed compound. NX-1207 treatment is administered by intraprostatic injection of a single dose by a urologist in an office setting. The entire procedure lasts on average 5-10 minutes, with the injection taking 1-2 minutes, and does not require anesthesia or catheterization.
Based on the past research interests of the CEO and the description of NX-1207 as a peptide, BioMedTracker believes NX-1207 to be either the 41 KD phosphoprotein AD7c-NTP (neural thread protein), or a derivative thereof. AD7c-NTP has been demonstrated to cause cells to enter apoptosis and impair mitochondrial function by an unknown mechanism.
Deal Structure: In December 2010, Recordati and Nymox Pharmaceutical announced the signing of a European licensing agreement for the development and commercialization of NX-1207.
Under the terms of the agreement, Recordati receives exclusive rights to develop and subsequently market and sell NX-1207 in Europe including Russia and the CIS, the Middle East, the Maghreb area of North Africa and South Africa (i.e. a total of 81 countries). The licensing agreement covers the use of NX-1207 for the treatment of BPH as the initial indication for development and commercialization. Recordati will make an upfront payment to Nymox of Euro 10 million (approximately USD 13 million); approval and sales milestones payments; and tiered supply and royalty payments of a minimum of 26% to increase progressively up to 40% of total net sales in the case specific contractual conditions are achieved.
Partners: Recordati SpA
Additional information available to subscribers only: